Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve

Executive Summary

Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.

Advertisement

Related Content

Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place
New Interim CAR-T Data Support Kite’s BLA Submission Plans
Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big
CAR-T Update: Kite's Filing Coming Soon
Juno Picks Up A2a Receptor Via Redox Acquisition
Juno ROCKETs On Fast Clinical Hold Resolution
Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register